172 related articles for article (PubMed ID: 32547195)
1. Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway.
Hu H; Liu Y; Tan S; Xie XX; He J; Luo F; Wang L
Cancer Manag Res; 2020; 12():3579-3587. PubMed ID: 32547195
[TBL] [Abstract][Full Text] [Related]
2. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade.
Yang Q; Ni L; Imani S; Xiang Z; Hai R; Ding R; Fu S; Wu JB; Wen Q
Cancer Manag Res; 2020; 12():4937-4948. PubMed ID: 32606981
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
Ji Y; Li X; Qi Y; Zhao J; Zhang W; Qu P
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558006
[TBL] [Abstract][Full Text] [Related]
5. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib suppressed tumor cell proliferation and migration in hypopharyngeal carcinoma.
Song H; Song Q; Zhao X; Yang Y; Mou Y; Li Y; Song X
Braz J Otorhinolaryngol; 2024; 90(2):101397. PubMed ID: 38330738
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
10. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity
Xu X; Wang Q; Shen L; Shen Y; Liu H; Liu Y; Yang Z; Hoffman RM; Feng W
Anticancer Res; 2024 Apr; 44(4):1399-1407. PubMed ID: 38538004
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis.
Zhu Y; Wang X; Chen Z; Zhou L; Di X; Fan P; He Z
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614964
[TBL] [Abstract][Full Text] [Related]
13. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
Song P; Song B; Liu J; Wang X; Nan X; Wang J
Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C.
Fang F; Yuan Q
Oncol Lett; 2022 Feb; 23(2):46. PubMed ID: 34976158
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.
Yuan M; Guo XL; Chen JH; He Y; Liu ZQ; Zhang HP; Ren J; Xu Q
Neoplasma; 2022 Jul; 69(4):807-819. PubMed ID: 35471977
[TBL] [Abstract][Full Text] [Related]
18. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
Liu X; Sun L; Zhang S; Zhang S; Li W
J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988
[TBL] [Abstract][Full Text] [Related]
19. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer.
Zheng W; Sun G; Li Z; Wu F; Sun G; Cao H; Zhou J; Ma Y
Front Surg; 2022; 9():895982. PubMed ID: 35495754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
